Linzagolix choline for treating moderate to severe symptoms associated with uterine fibroids in adult women of reproductive age

Linzagolix choline is currently in clinical development for the treatment of moderate to severe symptoms of uterine fibroids (UFs) in adult women. UFs are the most common form of benign uterine tumours, causing heavy menstrual bleeding, pelvic pain, infertility, and pressure symptoms. They can also cause bleeding between periods, anaemia, abdominal pain and cramping, painful sex, difficult, frequent, or urgent urination or bowel movements, increased abdominal size and miscarriage. However, there is a lack of safe treatment options available for this condition. Current therapy with progestins is often unsatisfactory, with many women treated by surgical intervention.